![In shock move, EU panel rejects Alzheimer's drug Leqembi](/sites/default/files/styles/x_large/public/2024-07/Leqembi%20denied.jpg?itok=2ryL2n2P)
In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Newsletters and Deep Dive digital magazine
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand
In new guidance, NICE has cleared NHS use of Boehringer Ingelheim's clot-busting therapy Metalyse as a treatment for acute ischaemic stroke in adults.
The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them
There are significant opportunities for pharma and biotech companies to support patients in the Middle East, but how do companies navigate such a culturally diverse region?
Editor's Picks
Newsletters and Deep Dive
digital magazine